Abigail Brooks, MA

Findings from a recent study of patients with IBD on biologic therapy suggest selenium and zinc deficiencies may predict disease outcomes and adverse clinical effects.

AbbVie submitted regulatory applications to the FDA and EMA for rizankizumab 1200 mg intravenous induction dose and 180 mg and 360 mg subcutaneous maintenance dose following successful Phase 3 trials INSPIRE and COMMAND.

Patients receiving systemic corticosteroids faced an increased risk of severe COVID-19 requiring hospitalization or mechanical ventilation compared to other medication classes used to treat IBD.

Hypertension prevalence was significantly higher among adults with obesity and severe NAFLD, providing important information related to the association between hypertension and NAFLD severity.

When evaluating patient-education strategies among individuals with IBD, investigators found vaccine uptake was unaffected by educational videos and text-based interventions, identifying prior vaccine receipt as the strongest predictor of future vaccination.

Diagnostic survey results indicated 62.7% of participating patients with hepatitis C expressed a low level of satisfaction with life.

Investigators identified a strong magnitude of association between MAFLD and risk of CKD based on the results of a comprehensive meta-analysis.

CKD-aP patients receiving maintenance hemodialysis reported adverse clinical events in line with their pruritus severity and were found to be at greater risk of all-cause mortality, all-cause hospitalization, and cardiovascular events.

A new study revealed differences in the diagnostic performance of the FIB-4 and NFS, indicating that conventional NFS cutoff values may be unsuitable for screening lean NAFLD patients.